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INHIBITION OF MAMMARY GROWTH BY HIGH DOSES OF ESTROGEN**
The administration of large doses of estrogen to young male mice was
followed by less extensive mammary gland growth than when small amounts
of estrogens were given". The areas occupied by the mammary glands of
the mice given large doses were often but little larger than the glands of
untreated controls, but unlike the controls their mammary glands, although
very small, had a few alveoli on the short, distended mammary ducts.
Mammary glands of restricted size were also observed in monkeys,2"
rabbits,' dogs,' and rats' given large doses of estrogens. The area of
proliferation of mammary glands of male mice was inversely proportional
to the amount of estrogens given beyond a certain optimal amount.'
The restricting effect of large doses of estrogen upon the area of non-
neoplastic mammary growth might be compared to the effects of large doses
of estrogen on neoplastic growth, especially in post-menopausal women.8
In neither instance has the mechanism for the inhibition or restriction of
growth been explained adequately.
Whether the large amounts of estrogen inhibit the growth of mammary
parenchyma by direct action or action upon the stroma, or whether the
effect is upon the pituitary gland or adrenal glands and hence upon the
mammary glands indirectly, is not known. Some experiments to determine
how large doses of estrogens inhibited mammary growth were undertaken.
MATERIALS AND METHODS
Male mice of the inbred CBA and C3H strains, first generation hybrid
mice (CC-C57 x CBA), and second generation hybrid mice (CC x CC)
were used in these experiments. Because the mammary gland and other
responses to the hormones that were used at different dose levels were
comparable among all genotype groups of mice, genetic and age influences
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within the ranges used were of no significance and will not be given
further consideration in the report of the observations. The mice ranged
from 15.1 to 23 gm. in weight at the start of the experiment and from 39-54
days in age. Most of the mice were treated for periods of three weeks.
The hormones* used were:
1. Estradiol benzoate (eb) dissolved in sesame oil so that 2 jug. was contained in
0.05 ml. Two jig. were injected subcutaneously every other day.
2. Estradiol benzoate in pellet form (EB). Each compressed pellet weighed 2-3
mg. and was implanted subcutaneously through a trocar.
3. Growth hormone (GH) was obtained in the desiccated form and dissolved in
saline just before use so that 0.05 ml. contained 0.1 mg. This was injected daily.
4. Lactogen (L) was also obtained in desiccated form, and dissolved in saline so
that 0.05 ml. contained 1 mg. This dose was injected subcutaneously once daily.
5. Progesterone (P) was compressed into pellets weighing about 10 mg. each.
Two pellets were implanted subcutaneously through a trocar at the beginning
of appropriate experiments.
6. Cortisone acetate (CA) supplied as a suspension was diluted so that 0.10 ml. of
suspension would contain 125 jtg. of hormone. This amount was injected sub-
cutaneously daily.
7. Adrenocorticotrophic hormone (AC) was injected subcutaneously at doses of
either one or two units daily (0.05 ml. of suspension contained one unit of
ACTH).
8. Relaxin (CR) was dissolved in benzopurpurine, so that 0.10 ml. of solution
contained 100 guinea pig units. This amount was injected subcutaneously every
four days.
9. Protamine Zinc Insulin, U.S.P. (I) was diluted with saline so that 0.05 ml.
contained 0.5 units. This amount was injected daily.
10. Desoxycorticosterone acetate (DO) was injected in daily doses of 250 ,g./0.05
ml.
11. Hyaluronidase (H) was dissolved in saline so that 0.10 ml. contained 1.5, 3.0 or
10.0 viscosity reducing units, and injected daily subcutaneously.
A method for determining the areas of the mammary glands was devised
to quantitate and compare the mammary responses. After the skin and
subcutaneous tela containing the mammary glands were removed, the skins
were stretched uniformly over cork boards and fixed in Bouin's solution.
After fixation, the glands and subcutaneous tela were removed from the
* The hormones and chemicals used in this investigation were: Estradiol benzoate, No.
14855, Organon, Inc., West Orange, New Jersey. Growth Hormone, Boving (SOMAR-
A) Lot R50109, Armour Laboratories, Kanakee, Illinois. Lactogenic Hormone
(PANLITAR), The Armour Laboratories, Lot No. R10109. Progesterone, USP, Lot
C2098, Mann Research Laboratories, Inc., New York, N. Y. Cortisone acetate
(CORTONE), Merck & Company, Inc. ACTH (CORTROPHIN-ZINC), Organon,
Inc., West Orange, New Jersey. Relaxin, Releasin R, Warner-Lambert Research Lab.,
Morris Plains, New Jersey. Protamine Zinc Insulin, Eli Lilly & Company, Indianapolis,
Indiana. DOCA (CORTATE), Schering Corporation, Bloomfield, New Jersey.
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skin, stained in Mayer's hemalum, suitably de-stained, dissected from
extraneous tissue, and prepared for mounting on glass slides after
dehydration and clearing in xylol.
Each slide so prepared was placed individually in a photographic
enlarger, as one would place a negative film for printing, and prints were
made on photographic paper at a uniform enlargement. The mammary
gland images were then cut out to include the area of paper within the
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FIG. 2. Total increases in body weight of groups of six mice given large doses of
estrogen (EB), large doses of EB + GH (growth hormone), or no treatment.
boundaries of the tips of the ducts or lobules. The total number of gland
image cut-outs from each mouse were weighed, and the total weight was
divided by the number of glands present to give the average "size" of the
mammary glands of each mouse in "weight units." The reasons for using
the average mammary gland response rather than the total response were
1) the numbers of mammary rudiments in different male mice range from
two to six, 2) some mammary rudiments are refractory under all condi-
tions, and 3) some glands may be damaged in preparation. This method of
appraising mammary area did not give the emphasis that measurements of
length times width would to glands of irregular shapes (for example,
glands with one unusually long duct).
611YALE JOURNAL OF BIOLOGY AND MEDICINE
c
0
E
E
0
._
-0
-o
EB ES eb eb eb eb eb eb eb eb eb eb eb
PP L AC P P P P4 P P P P
DO R Ac C mo t DO R I
18 9 EB
FIG. 3. Relative sizes of mammary glands of mice given different combinations of
hormone treatment (EB, large doses of estradiol benzoate; eb, small doses of estradiol
benzoate; L, lactogen; DO, desoxycorticosterone acetate; R, relaxin; ACTH, adreno-
corticotropic hormone; T, testosterone; I, insulin). Open vertical bars represent
standard error of the means of the treated groups.
OBSERVATIONS
Two major groups of experiments were undertaken. The first group
was designed to determine whether the inhibitory effect upon the mammary
gland of large doses of estrogens might be prevented by suitable supple-
mentation with other hormones (Fig. 1). The second group of experiments
was designed to determine whether the addition of other hormones to mice
612
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given small or optimal doses of estrogens for mammary growth might
inhibit mammary growth. Three types of control mammary glands were
considered: 1) those of untreated male mice (Fig. 5); 2) those of mice
given large amounts of estrogen (Fig. 6); and 3) those of mice given
smaller amounts of estrogen (Fig. 7).
The mammary rudiments of the untreated male mice were uniformly
small, an indication that they were not exposed to estrogen by contacts
or through food. Mice given large doses of estradiol benzoate (EB) had
mammary glands averaging less than 20 weight units (Table 1; Figs.
1 and 6); whereas mice given 2 Fg. of eb every other day had mammary
TABLE 1. THE SIZE OF MAMMARY GLANDS OF MICE GIVEN, OV'ER AN'
EIGHT-WEEK PERIOD, LARGE (EB) AND SMALL (eb) AMOUNTS OF
ESTRADIOL BENZOATE, WITH OR WITHOUT GROWTH HORMONE (GH)
Treatment Matmmary response in wzeight units
EB <20
EB and GH <20
eb 64±5.5
eb and GH 53 ± 3.5
glands that were more than three times as large (Figs. 1 and 7). These
observations affirm earlier observations."6
Not only were the mammary glands of the mice given eb larger in
size, as determined by the area occupied by the glands, but they were
structurally different, in that they were essentially branched tubular
structures with few or no alveoli and certainly no lobules (compare Fig.
7 with Figs. 8 and 9). The much smaller glands of the mice given EB
had many alveoli collected together to form lobules.
Young mice given large amounts of estrogen (EB) stop increasing in
body weight after about seven days. After five or six weeks a second
increase in weight may occur, but it is slight and is largely due to
increased urine retention. The possibility that the inhibition of mammary
growth by EB paralleled general inhibition of body growth was studied
by giving growth hormone to mice given EB. In this way essentially
normal body growth ensued (Fig. 2) but the mammary glands were as
small as in mice given EB alone. The inhibition of mammary growth was
not associated with a general deficiency of somatotrophic hormone.
613
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FIG. 4. Effects of cortisone acetate 125 i.&g./day on mammary size in mice also
treated with estrogen, with or without progesterone.
The suprarenal glands of individual mice given EB ranged from 32
to 35 mg. per 100 gm. body weight, whether or not growth hormone
was given, and were about 10 mg. per 100 gm. larger than those of mice
given eb. The increased adrenal size was due to hypertrophy of the cortex,
particularly the zona fasciculata. The bladders of the EB and the EB+GH
treated mice were similarly distended secondary to obstruction at the
614Photographs of Figs. 5-12 wcere takenl at the sanme miiagniificationi (5x).
FIG. 5. Mammllary gland of norm-ial male mouse consisted of ru(illelntary ducts, devoid
of smaller branchinig ducts or alveoli.
FIG. 6. Gland of male mouse was treated with high doses of estradiol benzoate (EB)
for eight weeks. Many alveoli arranged in lobules wvere comparable to the lobules seen
in the mammnary gland of a mouse at parturition. Lack of small ductule formationi, upoIn wlhich alveoli are formed, led to a "spotty" distribution of alveoli, in contrast to the
normal female gland. This gland was stunted in glandular area, as compared to Figure 7.
FIG. 7. Gland of male mouse, treated with eb for eight weeks. Alveolar growth was
lacking in contrast to those of mice treated with EB. This gland was much larger with
more numerous small ductule growth and numerous end budding.
FIG. 8. Mammary gland of male mouse treated with EB anid L, 2.5 mg./day for 80
days. The mammary areas wvere scarcely larger thani those of unitreated male mice
(Fig. 5). Alveolar growth was extensive, iinvolvinig the complete glandular area, with
secretion into the maini duct.
FIG. 9. Gland of mouse given EB and P, and CA (cortisonie). The gland resembled
that shown in Figure 8.
FIG. 10. Gland of mouse treated with eb and P for 21 days after an initial treatmelnt
of EB for four months. There was considerable ductule and alveolar growth, similar to
that of mice which were similarly treated but had not received the initial four-
month EB.
FIG. 11. In addition to eb and P, this mouse also received CA. The gland was smaller
but the number of small ducts and alveolar formations increased. Compare to Figure 12.
FIG. 12. Gland from mouse which received eb and P for three wveeks. There was
considerable small ductule growth, and early alveolar formation. Compare to Figure 11.FIG. 13. Mammary gland from mouse given eb, P and ACTH (18 units in 24 days).
Many lobules of alveolar were formed, beyond that seen in glands of mice not given
ACTH. These glands resemiibled qiualitatively glands of mice that also received CA
(Figure 11).
FIG. 14. Mammary gland from mouse given eb, P, and 100 g.p. uniits of relaxin every
four days, for three weeks. Similar glands developed in mice that received 0.5 ullits
insulini/day or lactogen 1 mg./day, plus eb and P. These were the largest glands seen
in this series, and showed small ductule aild alveolar growth of an extensive degree.
Compare to Figure 11.
FIG. 15. Gland from a mouse that received eb only. Growth was continuing as
evidenced by the prominient end clubs and the beginniing small ductule formation. Com-
pare with the gland shown in Figure 7, from a mouse given eb and P for 21 days.
FIG. 16. Mammary gland from a mouse that received CA in addition to eb. Qualita-
tively the gland was similar to that shown in Figure 15 with large end clubs and some
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proximal part of the cavernous urethra. The testes and seminal vesicles of
mice of both groups were small, indicating a decrease of gonadotrophic
hormone; the pituitary glands were enlarged slightly.
The simultaneous injection of progesterone (P) with either EB or eb
in young male mice resulted in larger mammary glands than in mice given
EB or eb alone (Figs. 1, 12 and 15). The relative differences in size
between the groups treated with EB and with eb were retained (Fig. 1).
The mammary glands of EB+P-treated mice ranged from 31 to 56
weight units and those of the eb+P-treated mice 71 to 87 weight units.
The mice given P as well as eb or EB had many more terminal ducts
and alveoli, and some partial formation of lobules (Fig. 12).
Mammary glands of nine mice given eb and nine mice given eb+L
were similar quantitatively and qualitatively (Fig. 3). Lactogenic hormone,
when injected in amounts of 1 mg. daily, did not modify the mammary
response to eb in intact young male mice. Furthermore, lactogenic
hormone injected in amounts of 2.5 mg. daily for 80 days did not modify
the mammary response of four male mice given EB (Fig. 8). The glands
measured little larger than the untreated controls but consisted of small
lobule-alveolar structures. Lactogenic hormone did not modify the growth
inhibition attending EB treatment.
Six male mice were given pellets of methyltestosterone subcutaneously,
and 45 days later were given eb and P for 21 days. The mammary
response was the same as in mice given eb and P alone (Fig. 3).
Relaxin (R)+P+EB and R+P+eb were each given to groups of nine
mice. The mammary response of the R+P+EB group were at the lower
range of the weight unit scale of the EB+P group and the two groups
were not significantly different from one another. The mammary glands
of the mice given R+P+eb averaged about 110 weight units or over
30 weight units more than the mice given P+eb for comparable periods.
The mammary glands of a group of five mice given 250 ,ug. of desoxycor-
ticosterone acetate daily with EB+P or eb+P did not differ significantly
from the mice given EB+P or eb+P alone (Fig. 3). Similar groups of
adrenalectomized mice given DO+EB+P or DO+eb+P had mammary
glands comparable to those of intact mice similarly treated.
Twelve mice were given a total of nine units of ACTH over a 24-day
period in addition to eb+P and 12 mice were given 18 units of ACTH
+eb +P during a comparable period. The sizes of the mammary glands
were not significantly different from those of the eb+P and EB+P
controls (Fig. 3). The glands, however, were much better developed in
that many lobules had developed and the amount of small terminal
615YALE JOURNAL OF BIOLOGY AND MEDICINE
branches had increased greatly (Fig. 13). Intrinsic adrenal cortical
hormones seemed to augment the formation of alveoli.
P+eb+insulin (I) were given to 10 mice. The mammary glands of
these mice were larger than those of mice given eb+P alone (Figs. 3
and 14). They resembled the glands of mice given relaxin. Not only were
the glands large but the numbers of small terminal ducts and partially
developed lobules were increased. Only one of 20 mice given P+EB+I
survived a significant part of the experimental period. Although this
one mouse had larger mammary glands than did mice given EB+P
the number of observations is too limited to be conclusive.
An attempt was made to determine whether the mammary growth
inhibitory effects of large amounts of estrogen (EB) would persist sub-
sequent to discontinuation of treatment. Twelve mice were given EB
for four months. After four months the pellets were removed and eb+P
were given for three weeks. The glands were comparable to those of
mice given eb+P alone for three weeks (Figs. 3 and 10). The mammary
inhibiting effect of EB was not irreversible because normal mammary
responses followed prolonged inhibition when more optimal hormonal
environments ensued.
The mammary glands of mice given eb or eb and P plus cortisone
acetate (Ca) were 40 to 70 per cent smaller than the glands of mice not
given the corticoid (see Fig. 4; compare Figs. 11 and 12; Figs. 15 and 16).
The mammary glands of the mice were given eb+P+Ca also had an in-
creased number of terminal ducts and lobules of small alveoli; in this respect
resembling the glands of mice that had been given eb+P for a longer
period. The mice given eb+Ca, however, showed little or no alveolar
development (Fig. 16). Cortisone seemed to augment the progesterone
effect on stimulation of alveolar proliferation but not the duct proliferating
effect of estrogens.
Mice given EB+P+Ca for three-week periods had small mammary
glands but showed extensive alveolar proliferation (Fig. 9). The glands
resembled those of mice given large amounts of estrogen plus lactogen
(Fig. 8). Cortisone thus reduced the extent of duct proliferation occurring
in mice given EB+P, tending especially to augment the effects of P (30
in contrast to 58 weight units, Fig. 4) and augment the alveolar prolifer-
ation.
Because the fatty mammary stroma around the terminal end buds of
the proliferating ducts is more basophilic it was at least interesting to
inject hyaluronidase (R) to determine its effects on mammary growth.
Eleven mice were given either 1.5, 3.0 or 10 units per day of hyaluronidase
616
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in addition to eb plus P for three weeks. The mammary glands were
similar in size and type of development to those of mice not given
hyaluronidase.
DISCUSSION
None of the hormones used prevented the restricted mammary growth
of mice given large amounts of estradiol benzoate (EB). Mice given
progesterone had larger mammary glands than did those given EB alone
but not as large as those given smaller amounts of estrogen (eb) and
progesterone (P). Mice given P had glands with more small ducts and
alveoli. The only possible exception was that insulin-treated mice given
EB+P might have had larger glands but the critical experiments could
not be done. The pituitary growth hormone and lactogenic hormone did
not reverse the mammary growth restriction of large amounts of estrogen,
but mice given these hormones had small glands with alveoli.
The mammary glands of young male mice given eb+P were larger
than those given eb alone and the effects of the added Ca largely in-
hibited the effects of P on ductal proliferation. However, the glands of
mice given eb+Ca resembled those of mice given EB. Cortisone acetate in
amounts of 125 pg. daily was the only hormone given that when given
in addition to small amounts of eb resulted in mammary growth approxi-
mately that seen in mice given EB. It seems improbable that the mechanism
whereby large amounts of estrogen inhibit mammary growth is through
the adrenal glands. Adrenalectomized mice given eb or EB plus desoxy-
corticosterone had mammary glands comparable to the controls given eb
or EB. The large doses of cortisone acetate may have acted as did the
large doses of estrogen. Cortisone seemed less detrimental to the prolifer-
ation of smaller ducts and alveoli than it did to the growth of the larger
ducts and in this manner again resembled EB. Both substances were
given at toxic levels and hence the responses should probably be con-
sidered in a pharmacological connotation rather than a physiological
one.
Although estrogens provoke little or no mammary growth in hypo-
physectomized mice they did induce growth of subjacent mammary tissue
when applied in very small amounts to the skin, and remote glands were
not influenced. 910 Small amounts of estrogens incite local mammary
growth in the presence of circulating levels of pituitary hormones and
hence seem to have a direct action on mammary tissue, but a dependent
one.
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It is probable that the large doses of estrogen may directly inhibit
mammary growth. Mammary growth is not inhibited in the same way as
somatic growth because the inhibitory effects of large amounts of estrogen
on somatic growth were prevented by growth hormone, but the mammary
glands remained small.
The mammary glands consist of both parenchyma and stroma. The
stroma is usually considered to be passive in most epithelial proliferative
processes. The mice experiments of Nandi' have revealed that fatty stroma
is essential for the proliferation of hyperplastic mammary nodules and the
same is also true for transplanted segments of mammary ducts.' The site
of action of estrogens in large amounts and of cortisone in large amounts
in the restriction of mammary proliferation may be upon the mammary
stroma rather than directly on the mammary parenchyma. The influences
of insulin and relaxin in augmenting the mammary responses might be
interpreted as acting on the stroma.
SUMMARY
1. Male mice given large doses of estradiol benzoate show little
extension of the mammary area but some increase in small ducts and a few
alveoli.
2. The injection of growth hormone, lactogen, relaxin, hyaluronidase,
adrenocorticotrophic hormone or desoxycorticosterone in addition to large
doses of estradiol benzoate did not modify the mammary response. Mice
given progesterone in addition to large doses of estradiol benzoate had
slightly larger mammary glands than those given EB alone.
3. Mammary growth of mice given smaller and near optimal amounts
of estrogen was inhibited by daily injections of 0.125 mg. of cortisone
acetate and resembled the glands of mice given large amounts of EB.
4. That large doses of estrogen did not inhibit mammary growth by
augmenting adrenal cortical function was indicated by 1) the similarity
of large and small doses of estradiol benzoate on the mammary glands
in adrenalectomized and intact mice given desoxycorticosterone, and 2)
effects of adrenocorticotrophic hormones when given in combination with
either large or small doses of estrogens.
5. Mice given either insulin, relaxin or lactogen in addition to small
doses of estrogen plus progesterone had larger glands than those given
estrogen and progesterone alone.
6. The over-all area of the mammary responses was determined
quantitatively by a "paper weight" method.
618
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